Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear. METHODS: In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5 050 patients with chronic heart failure (New York Heart Association class II, III, or IV) and an ejection fraction of less than 45% to receive vericiguat (target dose 10 mg once daily) or placebo, in addition to guideline-based medical therapy.The primary outcome was a composite of death from cardiovascular causes or first hospitalization for heart failure. RESULTS: Over a median of 10.8 months, a primary-outcome event occurred in 897 of 2 526 patients (35.5%) in the vericiguat group and in 972 of 2 524 patients (38.5%) in the placebo group (p = 0.02). A total of 691 patients (27.4%) in the vericiguat group and 747 patients (29.6%) in the placebo group were hospitalized for heart failure. Death from cardiovascular causes occurred in 414 patients (16.4%) in the vericiguat group and in 441 patients (17.5%) in the placebo group. The composite endpoint of death from any cause or hospitalization for heart failure occurred in 957 patients (37.9%) in the vericiguat group and in 1 032 patients (40.9%) in the placebo group (p = 0.02). Symptomatic hypotension occurred in 9.1% of the patients in the vericiguat group and in 7.9% of the patients in the placebo group (p = 0.12), syncope occurred in 4.0% of the patients in the vericiguat group and in 3.5% of the patients in the placebo group (p = 0.30). CONCLUSION: Among patients with high-risk heart failure, the incidence of death from cardiovascular causes or hospitalization for heart failure was lower among those who received vericiguat than those who received placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“From a safety perspective, there was more hypotension in the vericiguat group but this did not contribute to renal dysfunction, despite the relatively low eGFR cutoff for enrollment.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, the secondary end point of total HHF was also decreased in the vericiguat group (HR, 0.91 [95% CI 0.84-0.99]; P = 0.023).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The primary combined end point of CV death or first HHF was significantly lower (HR, 0.90 [95% CI 0.82-0.98]; P = 0.019) in the vericiguat group and this was driven primarily by a reduction in hospitalization rather than CV death.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationAngiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., Ikonomidis, J. S., Khavjou, O., Konstam, M. A., Maddox, T. M., et al. (2013) · Circulation: Heart Failure · doi:10.1161/hhf.0b013e318291329a · Cited by 2,804
Self-citationSoluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease
Stasch, J.-P., Pacher, P., & Evgenov, O. V. (2011) · Circulation · doi:10.1161/circulationaha.110.981738 · Cited by 601
Ruppar, T. M., Cooper, P. S., Mehr, D. R., Delgado, J. M., & Dunbar‐Jacob, J. M. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002606 · Cited by 415
Gheorghiade, M., Greene, S. J., Butler, J., Filippatos, G., Lam, C. S. P., Maggioni, A. P., Ponikowski, P., Shah, S. J., Solomon, S. D., Kraigher-Krainer, E., et al. (2015) · JAMA · doi:10.1001/jama.2015.15734 · Cited by 397
Self-citationClinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction
Butler, J., Yang, M., Manzi, M. A., Hess, G. P., Patel, M. J., Rhodes, T., & Givertz, M. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.049 · Cited by 245
Self-citationArmstrong, P. W., Roessig, L., Patel, M. J., Anstrom, K. J., Butler, J., Voors, A. A., Lam, C. S. P., Ponikowski, P., Temple, T., Pieske, B., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.08.013 · Cited by 208
Self-citation
Cited by
Items 501–600 of 1,000
Sex differences in diagnosis and treatment of heart failure: toward precision medicine
Lee, S. Y., & Park, S. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.338 · Cited by 10
“The only large-scale randomized controlled trial performed to date, VICTORIA, showed no significant sex-related differences in the efficacy or safety profile of vericiguat in patients with LVEF 45% [54].”
Harada, T., Kondo, H., Nakamura, K., He, Y., Goto, S., Takahashi, M., Yamasaki, H., Matsuda, N., Takano, M., Abe, I., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-24-0659 · Cited by 9
Song, Q., Wang, P., Wu, Y., Yao, Z., Wang, W., Tang, G., & Zhāng, P. (2025) · PeerJ · doi:10.7717/peerj.18978 · Cited by 11
“It operates by activating the NO-sGC-cGMP pathway, resulting in vasodilation and amelioration of cardiac remodeling ( Armstrong et al., 2020 ).”
Hypertension precision medicine: the promise and pitfalls of pharmacogenomics
Le, N. N., Frater, I., Lip, S. Z. L., & Padmanabhan, S. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2504865 · Cited by 15
Mapelli, M., Rubbo, F. M., Costantino, S., Amelotti, N., & Agostoni, P. (2025) · Cardiac failure review · doi:10.15420/cfr.2024.37 · Cited by 14
“27 Enrolled patients had to have had a recent ( 6 months) worsening HF event, with three prespecified subgroups (HF hospitalisation 3 months, 3–6 months, or worsening HF receiving outpatient intravenous diuretics at 3 months).”
Targeting the NO–sGC–cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure
Bajec, T., & Poglajen, G. (2025) · Cells · doi:10.3390/cells14171400 · Cited by 12
“The number needed to treat to prevent one primary event was 24—comparable to other therapies in similar high-risk cohorts over a relatively short follow-up [16].”
Key Issues in the Statistical Interpretation of Randomized Clinical Trials
Brophy, J. M. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.12.014 · Cited by 9
The challenges of an aging tetralogy of Fallot population
Woo, J. P., McElhinney, D. B., & Lui, G. K. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.1940960 · Cited by 9
“of hospitalization for heart failure in the VICTORIA trial [133].”
BackgroundMedical management of acute heart failure
Kamran, H., & Tang, W. H. W. (2021) · Faculty Reviews · doi:10.12703/r/10-82 · Cited by 14
Emerging concepts in heart failure management and treatment: focus on vericiguat
Kaplinsky, E., Perrone, S. V., & Barbagelata, A. (2023) · Drugs in Context · doi:10.7573/dic.2022-5-5 · Cited by 9
Reis, J., Gonçalves, A. V., Moreira, R. I., da Silva, T. P., Timóteo, A. T., Pombo, D., Carvalho, T., Correia, C., Santos, C., & Ferreira, R. C. (2023) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.03.006 · Cited by 10
Vericiguat for the treatment of heart failure with reduced ejection fraction
Siddiqi, A. K., Greene, S. J., Fudim, M., Mentz, R. J., Butler, J., & Khan, M. S. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2189101 · Cited by 10
“8% of the patients in the placebo group [31].”
BackgroundMethodResultInfluentialSelf-citationHeart Failure: Recent Advances and Breakthroughs
Sebastian, S. A., Co, E. L., Mahtani, A. U., Padda, I., Anam, M., Mathew, S. S., Shahzadi, A., Niazi, M., Pawar, S., & Johal, G. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101634 · Cited by 11
New Challenges in Heart Failure with Reduced Ejection Fraction: Managing Worsening Events
Lavalle, C., Lullo, L. D., Jabbour, J. P., Palombi, M., Trivigno, S., Mariani, M. V., Summaria, F., Severino, P., Badagliacca, R., Miraldi, F., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226956 · Cited by 12
“Vericiguat is the first medication approved by the European Medicines Agency (EMA) tested in patients with WHF while already on GDMT, with proven efficacy in reducing clinical events [31].”
BackgroundMethodInfluentialMedical Management and Device-Based Therapies in Chronic Heart Failure
Nguyen, A. H., Hurwitz, M., Abraham, J. A., Blumer, V. L., Flanagan, M. C., Garan, A. R., Kanwar, M. K., Kataria, R., Kennedy, J. L. W., Kochar, A., et al. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101206 · Cited by 14
“88 Despite the high risk of rehospitalization associated with signi fi cant health carecosts following incident HFH, use of GDMT in the year postdischarge did not change signi fi cantly, highlighting the need for earlier and greater implementation of GDMT. 84 The underutilization of medical therapy may be, in part, due…”
MethodInfluentialDarvishzadehdaledari, S., Harrison, A. S., Gholami, F., & Azadnia, A. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03640-x · Cited by 13
“HFrEF places a substantial healthcare burden, particularly for patients requiring rehospitalization or urgent outpatient care for heart failure, despite adhering to medical therapy based on established guidelines [6].”
BackgroundMustafa, D. M., Magdy, N., & Azab, N. F. E. (2023) · Scientific Reports · doi:10.1038/s41598-023-50097-1 · Cited by 14
Muk, B., Bánfi‐Bacsárdi, F., Vámos, M., Pilecky, D., Majoros, Z., Török, G., Vágány, D., Polgár, B., Solymossi, B., Borsányi, T., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14020131 · Cited by 19
Updates in pharmacotherapy of heart failure with reduced ejection fraction
Espinoza, C., Alkhateeb, H., & Siddiqui, T. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4640 · Cited by 9
“Please see Table 1 for a list of the drug classes currently in use for patients with HFrEF (9,28,40,45).”
BackgroundTreatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence
Koufou, E., Arfaras-Melainis, A., Rawal, S., & Kalogeropoulos, A. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020203 · Cited by 11
“In VICTORIA, a double-blind randomized trial, 5050 patients with LVEF < 45% and recent HF hospitalization or intravenous diuretic use were randomly assigned to either vericiguat or placebo [52].”
MethodMareev, Y. V., Gilarevsky, S. R., Begrambekova, Y. L., Lopatin, Y. M., Анатольевна, Г. А., Duplyakov, D. V., Kobalava, Z. D., Golukhova, E. Z., Koziolova, N. A., Панов, А. В., et al. (2021) · Kardiologiia · doi:10.18087/cardio.2021.4.n1639 · Cited by 9
Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice
Sinagra, G., Pagura, L., Stolfo, D., Fabris, E., Savarese, G., Rapezzi, C., Ferrari, R., & Merlo, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.017 · Cited by 12
Calamaras, T. D., Pande, S., Baumgärtner, R., Kim, S. K., McCarthy, J. C., Martin, G., Tam, K., McLaughlin, A. L., Wang, G., Aronovitz, M. J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.149075 · Cited by 9
“Agents which activate PKG1 through augmentation of cGMP, including nitrates (3), sacubitril/valsartan (4), and vericiguat (5), now represent a rapidly emerging class of drugs which have improved outcomes in heart failure with reduced ejection fraction.”
BackgroundGuidetti, F., Arrigo, M., Frank, M., Mikulicic, F., Sokolski, M., Aser, R., Wilhelm, M. J., Flammer, A. J., Ruschitzka, F. T., & Winnik, S. H. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.05.013 · Cited by 12
Diversity in modern heart failure trials: Where are we, and where are we going
Anaba, U., Ishola, A., Alabre, A. F., Bui, A., Prince, M., Okafor, H. E., Kola-Kehinde, O. O., Joseph, J. J., Mitchell, D., Odei, B. C. L., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.018 · Cited by 9
Ostrominski, J. W., & Vaduganathan, M. (2022) · Clinical Cardiology · doi:10.1002/clc.23849 · Cited by 11
“relative but greater absolute benefits in reducing readmission risks among high‐risk patients with worsening HFrEF, although inclusion of the latter in the current generation of HF‐focused guidelines is limited by lack of regulatory approval.(22,61,133,134) Once both are regionally approved and accessible, these thera…”
BackgroundMetabolomics Implicate Eicosanoids in Severe Functional Mitral Regurgitation
Hofbauer, T. M., Distelmaier, K., Muqaku, B., Spinka, G., Seidl, V., Arfsten, H., Hagn, G., Meier, S. M., Bartko, P. E., Pávó, N., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14160 · Cited by 8
Innovations in medical therapy of heart failure with reduced ejection fraction
Mercurio, V., Ambrosio, G., Correale, M., Dini, F. L., Ghio, S., Nodari, S., Palazzuoli, A., Ruocco, G. M., Pedrinelli, R., Mercuro, G., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001413 · Cited by 10
Yang, Y. L., Gao, J., Qin, Z., Lu, Y., Xu, Y., Guo, J., Cui, X., Zhang, J., & Tang, J. (2023) · Intensive Care Research · doi:10.1007/s44231-023-00029-4 · Cited by 8
“Clinical trials have shown that administering sGC stimulators in patients with decompensated HF reduces mortality from cardiovascular causes as well as hospitalizations for HF [27].”
BackgroundCorreale, M., Tricarico, L., Croella, F., Alfieri, S., Fioretti, F., Brunetti, N. D., Inciardi, R. M., & Nodari, S. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1157472 · Cited by 12
“Elamipretide, studied both to maintain cellular biogenetics and prevent ROS-induced cell injury, has shown to increase LVEF and prevent LV remodeling in animal models of HFrEF.”
MethodInfluentialBauersachs, J. K., & Olsson, K. M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac387 · Cited by 9
Contributors and Solutions to High Out-of-Pocket Costs for Heart Failure Medications
Lowe, E. F., Gerasta, D. J., Balser, M., Page, R. L., II, Tsai, E., Biermann, H., Mitchell, A. R., Chan, D., Matlock, D. D., Dickert, N. W., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.011 · Cited by 10
Dhahri, W., Dussault, S., Raguema, N., Desjarlais, M., & Rivard, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.017 · Cited by 11
Ji, L., Mishra, M., & Geest, B. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041092 · Cited by 9
Eligibility for Vericiguat in a Real-World, Contemporary Heart Failure Population
Vergaro, G., Aimo, A., Gentile, F., Mandoli, G. E., Focardi, M., Castiglione, V., Giannoni, A., Panichella, G., Fornaro, A., Carluccio, E., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14767 · Cited by 7
New Therapeutics for Heart Failure Worsening: Focus on Vericiguat
Russo, P., Vitiello, L., Milani, F., Volterrani, M., Rosano, G. M. C., Tomino, C., & Bonassi, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144209 · Cited by 10
“…(NYHA) Classification class II–IV, elevated natriuretic peptide concentrations, and WHF WHF was defined as an HF hospitalization within 6 months before randomization or an episode of decompensation with outpatient treatment using intravenous furosemide 3 months before randomization [8,9].”
MethodDiabetes and Heart Failure: A Literature Review, Reflection and Outlook
Li, X., Zhou, X., & Gao, L. (2024) · Biomedicines · doi:10.3390/biomedicines12071572 · Cited by 11
Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?
Correale, M., Pelaggi, G., Catanoso, M. C., Miccichè, S., Teresi, L., Bonanno, S., Bellocchi, P., Poleggi, C., Capasso, R., Barile, M., et al. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10425-7 · Cited by 8
“While vericiguat did not worsen GFR in these trials, its effects in patients with GFR 15 ml/min were not explored [25, 26].”
Polhemus, D. J., Almodiel, D., Harb, T., Ziogos, E., Amat-Codina, N., Ranek, M. J., Santhanam, L., Gerstenblith, G., & Leucker, T. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-88938-w · Cited by 12
Le, N. N., Tran, T., McClure, J., Gill, D., & Padmanabhan, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf015 · Cited by 9
Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways
Nubbemeyer, K., Krabbe, J., Böll, S., Michely, A., Kalverkamp, S., Spillner, J. W., & Martin, C. (2025) · Biomedicines · doi:10.3390/biomedicines13040856 · Cited by 8
“It is considered a suitable treatment for cardio-vascular disease [14], as it has been shown to reduce the risk of death and the need for hospitalization in patients with heart failure with reduced ejection fraction [15].”
Feo, D. D., Massari, F., Campanella, C., Livrieri, A., Ciccone, M. M., Caldarola, P., Palo, M. D., & Scicchitano, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104550 · Cited by 10
“Notably, the VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA) trial [12] recently demonstrated a 10% reduction in the composite risk of all-cause mortality or hospitalization for heart failure (HF) with Vericiguat, a soluble guanylate cyclase…”
Michieli, L. D., Lupi, A., Sinigiani, G., Tietto, A., Salvalaggio, A., Branca, A., Pozzo, S. D., Rizzo, S., Cecchin, D., Marra, M. P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103481 · Cited by 10
“While these therapies have undeniably shown benefits in other forms of HF [28–30], their safety and efficacy in patients with this disease remain unstudied.”
Treatment of pulmonary hypertension after seven world symposia
Estrada, R. A., Sahay, S., & Tonelli, A. R. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251342898 · Cited by 10
“90 97 This refined categorization reflects the unique pathogenic mechanisms at play in each condition, allowing for a more precise and targeted approach to diagnosis and treatment.”
Romanò, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145090 · Cited by 9
“Recent trials involving sodium–glucose cotransporter 2 inhibitors (SGLT2i) used a cutoff of LVEF ≤ 40%, while the Victoria study with vericiguat applied a cutoff of 45%, despite targeting patients with HFrEF [33].”
Naidu, A. S., Ambrosy, A. P., Cotter, G., Bocchi, E. A., Butler, J., Chioncel, O. D., Davison, B. A., Dzudié, A., Freund, Y., Fudim, M., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15389 · Cited by 10
Self-citationLuedde, M., Agewall, S., Ambrosio, G., Bayés‐Genís, A., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70069 · Cited by 11
Yoshikawa, T. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.02.008 · Cited by 10
Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update
Hellenkamp, K., Nolte, K., & von Haehling, S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2047647 · Cited by 9
“vericiguat daily compared to placebo in addition to guideline-based medical therapy in 5050 symptomatic (NYHA II– IV) HF-patients with an LVEF ≤45%, an elevated natriuretic peptide level, and a recent episode of worsening HF[36].”
MethodEfficacy and safety of vericiguat in heart failure: a meta-analysis
Ma, J., Guo, S., Jiang, H., & Li, B. (2023) · Journal of International Medical Research · doi:10.1177/03000605231159333 · Cited by 8
“In the VICTORIA trial, vericiguat showed no advantage over placebo in improving the EF in patients with EF 40%, and patients in both groups experienced similar progression.(11,19) A recent network meta-analysis focusing on therapies for HF indicated that vericiguat was less efficient than b-blockers for reducing all-c…”
ResultNúñez‐Marín, G., Iraola-Viana, D., Lorenzo, M., de la Espriella, R., Villar, S., Santas, E., Miñana, G., Sanchís, J. M., Carratalá, A., Miró, Ò., et al. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2216386 · Cited by 9
“endpoint only in subjects with NT-proBNP up to 8000 pg/mL [104,105].”
BackgroundTrinkley, K. E., Dafoe, A., Malone, D. C., Allen, L. A., Huebschmann, A. G., Khazanie, P., Lunowa, C., Matlock, D. D., Suresh, K., Rosenberg, M. A., et al. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13885 · Cited by 12
Vericiguat protects against cardiac damage in a pig model of ischemia/reperfusion
Zhu, W., Ben, Y., Shen, Y., & Liu, W. (2023) · PLoS ONE · doi:10.1371/journal.pone.0295566 · Cited by 9
Olivella, A., Bonet, L. A., Moliner, P., Coloma, E., Martínez‐Rubio, A., Bermejo, M. P., Boixeda, R., Cediel, G., Méndez, A. B., & Fácila, L. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14647 · Cited by 8
“11,34,37,42 All these data show that to reduce HF burden, it is necessary to implement all disease-modifying HF therapies, adjusted according to the clinical pro fi le of patients.”
BackgroundInfluentialCurrent experimental and early investigational agents for cardiac fibrosis: where are we at?
Ciampi, C. M., Sultana, A., Ossola, P., Farina, A., Fragasso, G., & Spoladore, R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326024 · Cited by 8
“Recent insights from the VICTORIA study highlighted the capability of vericiguat to decrease heart failure-related hospitalizations and associated cardiovascular complications [79].”
BackgroundCunha, M. S., Lacchini, R., & Tanus-Santos, J. E. (2024) · Antioxidants · doi:10.3390/antiox13060691 · Cited by 13
“The results revealed more remarkable survival in patients who received the drug than those who received a placebo [47].”
BackgroundShoji, S., & Mentz, R. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10412-y · Cited by 10
“Firstly, although most prespecified subgroup analyses showed consistent treat-ment effects across all subgroups [24, 29–31], patients in the highest quartile of N-terminal pro–B-type natriuretic peptide (> 5314 pg/mL) appeared to have less benefit from vericiguat.”
InfluentialPharmacologic therapy for pulmonary artery hypertension
Nair, A. P. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000796 · Cited by 9
“Vericiguat is an sGC stimulator that is optimized to allow for once-daily dosing and has demonstrated efficacy in reducing hospitalizations for heart failure with reduced ejection fraction [35].”
BackgroundNew Drugs for Heart Failure: What is the Evidence in Older Patients?
Orso, F., Herbst, A., Pratesi, A., Fattirolli, F., Ungar, A., Marchionni, N., & Baldasseroni, S. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.011 · Cited by 10
Fucili, A., Cimaglia, P., Severi, P., Giannini, F., Boccadoro, A., Micillo, M., Rapezzi, C., Tavazzi, L., & Ferrari, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194325 · Cited by 8
Vericiguat Improves Aortic Wave Reflection Parameters in a New Preclinical Model of Hypertension
Boden, K., Sandner, P., Roessig, L., Vogel, J. K., Chirinos, J. A., & Mondritzki, T. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008735 · Cited by 8
Self-citationCarnicelli, A., Clare, R. M., Hofmann, P., Chiswell, K., DeVore, A. D., Vemulapalli, S., Felker, G. M., Kelsey, A. M., DeWald, T. A., Sarocco, P., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.12.003 · Cited by 7
Villevalde, S. V., & Soloveva, A. E. (2021) · Kardiologiia · doi:10.18087/cardio.2021.12.n1860 · Cited by 8
Drug Treatment of Heart Failure in Children: Gaps and Opportunities
Weisert, M., Su, J. A., Menteer, J., Shaddy, R. E., & Kantor, P. F. (2022) · Pediatric Drugs · doi:10.1007/s40272-021-00485-9 · Cited by 9
“In the recently reported VICTORIA trial, adult patients with chronic symptomatic HFrEF and an EF of < 45% were monitored for a composite endpoint of cardiovascular death or first HF hospitalization [107].”
BackgroundGreene, S. J., Lautsch, D., Gaggin, H. K., Djatche, L. M., Zhou, M., Song, Y., Signorovitch, J., Stevenson, A. S., Blaustein, R. O., & Butler, J. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.05.016 · Cited by 8
Self-citationReal-Life Data on Readmissions of Worsening Heart Failure Outpatients in a Heart Failure Clinic
Inácio, H., Carvalho, A. D., Carvalho, J. G. D., Maia, A., Durão-Carvalho, G., Duarte, J., Rodrigues, C., Araújo, I., Henriques, C. C., & Fonseca, C. (2023) · Cureus · doi:10.7759/cureus.35611 · Cited by 8
“In 2020, the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) study showed that vericiguat decreased the incidence of death from cardiovascular causes or hospitalization for HF among patients with high-risk HF [26].”
BackgroundDíez‐Villanueva, P., Jiménez-Méndez, C., Pérez-Rivera, J.-Á., Esteban‐Fernández, A., Datino, T., Martínez‐Sellés, M., & Ayesta, A. (2023) · Cardiology · doi:10.1159/000530424 · Cited by 10
Lee, M. M. Y., & Sattar, N. A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15085 · Cited by 11
“Vericiguat, a soluble guanylate cyclase stimulator, has a Class IIb recommendation for HF with an LVEF 45% and recent hospitalization for HF, 80 but should be added only after other GDMT has been optimized (Data S1, Table S7).”
BackgroundHarrington, J., Sun, J., Fonarow, G. C., Heitner, S. B., Divanji, P., Binder, G., Allen, L. A., Alhanti, B., Yancy, C. W., Albert, N. M., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028820 · Cited by 9
Effects of Angiotensin 1-7 and Mas Receptor Agonist on Renal System in a Rat Model of Heart Failure
Cohen-Segev, R., Nativ, O. F., Kinaneh, S., Aronson, D., Kabala, A., Hamoud, S., Karram, T., & Abassi, Z. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411470 · Cited by 8
“Similar results were obtained in clinical trials where treatment with Vericiguat lowered the incidence of death from cardiovascular causes or hospitalization for heart failure among patients with heart failure and reduced ejection fraction [52].”
ResultYogasundaram, H., Zheng, Y., Ly, E., Ezekowitz, J. A., Ponikowski, P. P., Lam, C. S. P., O’Connor, C. M., Blaustein, R. O., Roessig, L., Temple, T., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3021 · Cited by 8
Self-citationDiagnosing post-capillary hypertension in patients with left heart disease: impact of new guidelines
Güder, G., Reiter, T., Fette, G., Hundertmark, M., Frantz, S., Morbach, C., Störk, S., & Held, M. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02290-5 · Cited by 8
“Recently, the soluble guanylate cyclase stimulator (sGC) Vericiguat effectively reduced the primary endpoint in patients with HFrEF, mainly by lowering the risk for HF hospitalisations [32].”
Frechen, S., Ince, I., Dallmann, A., Gerisch, M., Jungmann, N. A., Becker, C., Lobmeyer, M. T., Trujillo, M. E., Xu, S. S., Burghaus, R., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13059 · Cited by 7
“Specifically, the goals of this study were: 1.”
BackgroundLatest pharmaceutical approaches across the spectrum of heart failure
Bismpos, D., Wintrich, J., Hoevelmann, J., & Böhm, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10389-8 · Cited by 11
“Recently, the VICTORIA trial demonstrated significantly lower rates for cardiovascular death and HF hospitalizations among patients with symptomatic HF (NYHA II-IV) and a reduced LVEF of ≤ 45% [36].”
BackgroundBenkner, A., Rüdebusch, J., Nath, N., Hammer, E., Grube, K., Groß, S., Dhople, V. M., Eckstein, G., Meitinger, T., Kaderali, L., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15910 · Cited by 10
“Interestingly, a recently published clinical trial from Armstrong et al. (2020) showed that the sGC stimulator vericiguat reduced the incidence of the composite of death from cardiovascular causes or hospitalisation for HF in patients with high-risk HFrEF.”
BackgroundMetabolic Syndrome and Pharmacological Interventions in Clinical Development
Javor, E., Šarčević, D., & Rešić, A. (2024) · Diabetology · doi:10.3390/diabetology5030023 · Cited by 9
Natale, F., Fusco, C., Stigliani, R., Golino, P., & Cimmino, G. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132467 · Cited by 7
Araújo, C. S., Clement, I. M., Restrepo-Córdoba, M. A., Costa, I. V., Pérez‐Villacastín, J., & Artaza, J. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237171 · Cited by 7
Esteban‐Fernández, A., Mayoral, A. R., López‐Vilella, R., de Lara, G., Barrantes-Castillo, M., Otero, I. G., Núñez, J. E., Robles‐Gamboa, C., Aguilera, J. L., Iniesta-Manjavacas, Á. M., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1504427 · Cited by 7
“In the VICTORIA trial, vericiguat reduced cardiovascular (CV) mortality and heart failure (HF) hospitalisations in high-risk patients with HF and reduced ejection fraction (HFrEF) when added to optimal medical therapy compared to placebo (3).”
Gouda, P., Alemayehu, W. G., Voors, A. A., Lam, C. S. P., Ezekowitz, J. A., Pieske, B. M., Butler, J., Westerhout, C. M., Yogasundaram, H., Sandhu, R. K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3731 · Cited by 8
Self-citationPediatric heart failure: Current approach and treatment
Olsen, B. A., & Miyamoto, S. D. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100331 · Cited by 11
“60 A phase II/III RCT of vericiguat vs placebo (VALOR) is presently underway in children.”
Ferro, A., Segreti, A., Crispino, S. P., Cricco, R., Cristo, A. D., Ciancio, M., Gurrieri, F., Ussia, G. P., & Grigioni, F. (2025) · Genes · doi:10.3390/genes16070801 · Cited by 10
“Vericiguat, a soluble guanylate cyclase stimulator, may be added in HFrEF patients with recent decompensation despite standard therapy [8].”
Mentz, R. J., Butler, J., McMullan, C. J., WOJDYLA, D. M., Anstrom, K. J., Barash, I., Bonaca, M. P., Borentain, M., Corda, S., Ezekowitz, J. A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70033 · Cited by 7
Self-citationHeart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Escobar, C., Luis-Bonilla, J., Crespo-Leiro, M. G., Esteban‐Fernández, A., Farré, N., García‐Álvarez, A., & Núñez, J. E. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2116275 · Cited by 8
“treatment, including sacubitril/valsartan, and time since HFrelated hospitalization or an HF-related decompensation episode [54,58].”
MethodMozzini, C., & Pagani, M. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101834 · Cited by 7
McChord, J., Pereyra, V. M., Froebel, S., Bekeredjian, R., Schwab, M. G., & Ong, P. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1156456 · Cited by 8
Ichihara, Y. K., Kohsaka, S., Kisanuki, M., Sandhu, A. T., & Kawana, M. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.07.019 · Cited by 8
Bánfi‐Bacsárdi, F., Vámos, M., Majoros, Z., Török, G., Pilecky, D., Duray, G. Z., Kiss, R. G., Nyolczas, N., & Muk, B. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32836 · Cited by 12
Pulmonary Hypertension Associated with Left Heart Disease
Baratto, C., Caravita, S., & Vachiéry, J. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1772754 · Cited by 9
Ajay, A., Rasoul, D., Abdullah, A., En, B. L. W., Mashida, K., Al-Munaer, M., Ajay, H., Duvva, D., Mathew, J., Adenaya, A., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2290064 · Cited by 8
“Vericiguat has been approved by FDA in January 2021 in patients with symptomatic chronic heart failure with EF 45% or less [110,111].”
BackgroundInfluentialUse of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy
Magavern, E. F., Kapil, V., Saxena, M., Gupta, A. K., & Caulfield, M. J. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319220 · Cited by 10
Kourek, C., Briasoulis, Α., Papamichail, A., Xanthopoulos, A. V., Tsougos, E., Farmakis, D. T., & PARASKEVAIDIS, I. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063113 · Cited by 14
“The safety profile of vericiguat was also assessed in the VICTORIA trial [49].”
BackgroundMethodResultInfluentialGupta, S. D., Butt, J. H., McMurray, E. G. M., Talebi, A., Matsumoto, S., Rizkala, A. R., Henderson, A. D., Desai, A. S., Lefkowitz, M. P., Packer, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3515 · Cited by 7
Santiago‐Vacas, E., García‐Lunar, I., Solanes, N., Dantas, A. P., Ascaso, M., Jimenez‐Trinidad, F. R., Ramírez, J., Fernández‐Friera, L., Galán‐Arriola, C., Sánchez, J., et al. (2020) · Translational research · doi:10.1016/j.trsl.2020.08.006 · Cited by 7
Larina, V. N., Skiba, I. K., & Skiba, A. S. (2022) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4820 · Cited by 11
Kishino, Y., Kuno, T., Malik, A. H., Lanier, G. M., Sims, D. B., Duque, E. R., & Briasoulis, Α. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13956 · Cited by 7
“In addition to the conventional standard care, recent medical progress developed several therapies, such as sacubitril-valsartan,(1,2) inhibitors of sodium–glucose cotransporter 2 (SGLT2),(3,4) ivabradine,(5) and vericiguat.(6) These medical therapies are effective and im-”
BackgroundHyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy
Murphy, D., & Banerjee, D. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00552-3 · Cited by 7
“5% in the placebo group over a median follow-up of 11 months [46].”
BackgroundBecker, C., Böettcher, M., Muenster, U., Loewen, S., Lobmeyer, M. T., & Mueck, W. (2022) · AAPS Open · doi:10.1186/s41120-022-00063-4 · Cited by 7
Böettcher, M., Nowotny, B., Krausche, R., & Becker, C. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01203-5 · Cited by 7
“Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction at therapeutic doses of 25–100 mg [5, 6], is a potential co-medication in male patients receiving vericiguat for the treatment of HFrEF.”
MethodResultInfluential
Metadata
- Authors
- Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., McNulty, S. E., Patel, M. J., Roessig, L., Koglin, J., & O’Connor, C. M.
- Affiliations
- University of Alberta (CA)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inova Health System (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-14
- Volume
- 382
- Issue
- 20
- Pages
- 1883-1893
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013207865
- Semantic Scholar
- f98a684f8b44644864e75febeca130b492e75a2c
- Cited by
- 1,358
- References
- 17
- Citations by year
- 2026: 170 · 2025: 213 · 2024: 189 · 2023: 253 · 2022: 225 · 2021: 207 · 2020: 96
- FWCI
- 121.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Bayer
- Merck
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- vericiguat, heart failure with reduced ejection fraction, soluble guanylate cyclase stimulator, cardiovascular mortality, heart failure hospitalization, symptomatic hypotension, syncope, chronic heart failure
- MeSH terms
- Soluble Guanylyl Cyclase, Administration, Oral, Aged, Cardiovascular Diseases, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Heterocyclic Compounds, 2-Ring, Hospitalization, Humans, Hypotension, Male, Middle Aged, Pyrimidines, Stroke Volume, Syncope, Incidence, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.